Related Experiment Videos
Aberrant TSG101 transcripts in acute myeloid leukaemia
1Department of Internal Medicine, Kaohsiung Medical College Hospital, Taiwan.
British Journal of Haematology
|August 29, 1998
Summary
Aberrant tumor susceptibility gene 1 (TSG101) transcripts were found in 35% of acute myeloid leukemia patients and 100% of cell lines. Further research is needed to clarify TSG101
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Tumor susceptibility gene 1 (TSG101) is located at chromosome 11p15.
- A large intragenic deletion of TSG101 has been observed in primary breast tumors.
- The role of TSG101 in the development of leukemia requires further investigation.
Purpose of the Study:
- To investigate the presence and significance of TSG101 gene alterations in acute myeloid leukemia (AML).
- To analyze TSG101 mRNA expression in AML patients, hematopoietic cell lines, and normal controls.
Main Methods:
- Analysis of bone marrow and peripheral blood samples from 68 AML patients and 30 healthy individuals.
- Examination of five human hematopoietic cell lines (HL60, U937, Raji, KG-1, K562).
- Reverse transcription of TSG101 mRNA, followed by PCR amplification and sequencing.
Main Results:
- Aberrant TSG101 transcripts were detected in 35% of AML patients (24/68).
- All tested hematopoietic cell lines (100%) exhibited aberrant TSG101 transcripts.
- Aberrant transcripts were also found in 10% of normal controls (3/30), suggesting potential alternative splicing.
Conclusions:
- Aberrant TSG101 transcripts, likely arising from alternative RNA splicing, are more frequent in AML and cell lines.
- The presence of aberrant TSG101 transcripts in normal controls necessitates careful evaluation of its role as a tumor suppressor gene.
- Further studies are required to elucidate the precise function of TSG101 in leukemogenesis.